# A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy

> **NCT03404791** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 35 (actual)

## Conditions studied

- Urinary Bladder Neoplasms

## Interventions

- **DRUG:** TAR-200

## Key facts

- **NCT ID:** NCT03404791
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-20
- **Primary completion:** 2019-12-23
- **Final completion:** 2022-09-15
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2025-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404791, "A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03404791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*